Concurrent with the appointment of Mr. Meadows, OncoOne has established a United States subsidiary in Boston, Massachusetts: OncoOne US Inc., which Mr. Meadows will lead as General Manager. OncoOne US Inc. will be the base for the company’s future business development activities.
“Brent has built an impressive track record in a range of key leadership positions for his ability to drive global strategic collaborations and establish foundational business practices, resulting in a large number of successful agreement and licensing partnerships,” said Randolf Kerschbaumer, Ph.D., CEO of OncoOne. “As we continue to advance our novel monoclonal antibodies targeting oxidized macrophage migration inhibitory factor (oxMIF) through the early stages of drug development and continue to expand our pipeline, Brent’s experience will be important in setting a corporate strategy that further positions OncoOne as an emerging leader in precision therapeutics for cancer and other diseases.”
“OncoOne is rapidly progressing toward becoming a clinical-stage company with a unique opportunity based in their proprietary knowledge of oxMIF and oxMIF’s potential in a broad range of blockbuster indications,” said Brent Meadows, Chief Business Officer of OncoOne. “I am humbled and honored to join OncoOne’s world-class research team to help expand their future development and partnering opportunities.”
Before joining OncoOne, Mr. Meadows served as the commercialization lead for many of Biogen’s pipeline assets. Prior to Biogen, Mr. Meadows led the commercial insights into Baxalta’s (then Shire’s) oncology pipeline. Mr. Meadows’ background includes various senior marketing leadership roles in which he led launch marketing efforts and successful licensing partnerships at Baxalta, Bristol Myers Squibb, Regeneron, and Johnson & Johnson. As the first commercial hire at AVEO Oncology, Mr. Meadows served as the co-program executive for FOTIVDA® (tivozanib) helping to create the scientific narrative and expert engagement which led to the $1.4 billion collaboration with Astellas and the EMEA approval. Mr. Meadows holds an MBA from the Babson F.W. Olin Graduate School of Business and a Bachelors of Business Administration from the University of Richmond..
OncoOne seeks to overcome the limitations of targeting macrophage migration inhibitory factor by harnessing the high tumor-specificity of the disease-related isoform, oxidized macrophage migration inhibitory factor (oxMIF). The Company is focused on developing multiple proprietary drug modalities to leverage oxMIF’s potential as a target for systemic treatment of pancreatic, colorectal, ovarian and lung cancer, as well as for chronic inflammatory diseases. Equipped with a successful track-record in early-stage drug development, as well as a deep understanding of the target itself, OncoOne’s leadership will advance a pipeline based on oxMIF’s promise in oncology and other disease areas. www.oncoone.com